ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer

Petit, Robert G.; Mehta, Ajay; Jain, Minish; Gupta, Sudeep; Nagarkar, Rajnish; Kumar, Vijay; Premkumar, Sumana; Neve, Rakesh; John, Subhashini; Basu, Partha

doi:10.1186/2051-1426-2-s3-p92

Cited by 15 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In India, 110 patients with recurrent disease were randomized to three to four doses of AXAL with or withour weekly cisplatin 40 mg/m 2 . More than a third of patients had stable disease or responses (including five complete responses) and 2- year overall survival was 18% across both treatment arms 36. The addition of cisplatin did not appear to improve outcomes compared with AXAL alone.…”

Section: Beyond Checkpoint Blockade: Emerging Immunotherapeutic Appro...mentioning

confidence: 86%

Advances in immunotherapy for cervical cancer: recent developments and future directions

Sherer

Kotha

Williamson

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

There is an unmet need for novel therapies to improve clinical outcomes for patients with locally advanced, recurrent, or metastatic cervical cancer. Most cases of cervical cancer are driven by infection with human papillomavirus (HPV), which uses multiple mechanisms to avoid immune surveillance. Several classes of agents have been developed that seek to activate the immune system in order to overcome this resistance and improve treatment outcomes. These include immune checkpoint inhibitors, therapeutic vaccines, engineered T cells, and antibody-drug conjugates. Here, we review the immune landscape of cervical cancer and the growing clinical data regarding the use of immunotherapy. Checkpoint inhibitors are the best studied treatments, with encouraging phase II studies available in the definitive setting and recently published phase III data defining a new standard of care for patients with recurrent or metastatic disease. Vaccines and engineered T cells are generally in earlier phases of development but use unique mechanisms of immune activation. It is possible that combination of immunotherapy, with either conventional systemic therapy or multiple immunomodulatory agents, may provide further benefit. We also discuss possible synergies between immunotherapy and radiation therapy, which is frequently used in the management of cervical cancer. Ultimately, immunotherapy represents an emerging treatment option for patients with cervical cancer. It is an appropriate component of first-line treatment in the recurrent or metastatic setting and may soon be incorporated into definitive management of locally advanced disease.

show abstract

Section: Beyond Checkpoint Blockade: Emerging Immunotherapeutic Appro...mentioning

confidence: 86%

Advances in immunotherapy for cervical cancer: recent developments and future directions

Sherer

Kotha

Williamson

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…A phase II trial has observed an OS of 38% in CC patients in progression after one or two lines of CT treated with recombinant live attenuated L. Monocytogenes equipped in vitro with the ability to secrete the fusion protein E7- non-hemolytic listeriolysin O (Lm-LLO-E7). The phase III is currently ongoing and is expected to be completed in October 2024 [ 77 ].…”

Section: Vaccinesmentioning

confidence: 99%

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?

Turinetto

Valsecchi

Tuninetti

et al. 2022

IJMS

View full text Add to dashboard Cite

The prognosis of invasive cervical cancer (CC) remains poor, with a treatment approach that has remained the same for several decades. Lately, a better understanding of the interactions between the disease and the host immune system has allowed researchers to focus on the employment of immune therapy in various clinical settings. The most advanced strategy is immune checkpoint inhibitors (ICIs) with numerous phase II and III trials recently concluded with very encouraging results, assessing single agent therapy, combinations with chemotherapy and radiotherapy. Apart from ICIs, several other compounds have gained the spotlight. Tumor Infiltrating Lymphocytes (TILs) due to their highly selective tumoricidal effect and manageable adverse effect profile have received the FDA’s Breakthrough Therapy designation in 2019. The antibody drug conjugate (ADC) Tisotumab-Vedotin has shown activity in metastatic CC relapsed after at least one line of chemotherapy, with a phase III trial currently actively enrolling patients. Moreover, the deeper understanding of the ever-changing immune landscape of CC carcinogenesis has resulted in the development of active therapeutic vaccines. This review highlights the different immunotherapeutic strategies being explored reflects on what role immunotherapy might have in therapeutic algorithms of CC and addresses the role of predictive biomarkers.

show abstract

“…So are clinical trials of other algorithms. Bacteria‐vector vaccine ADXS11‐001 without cisplatin was found no different survival outcome and tumor response but a safety profile compared to with cisplatin .A phaseIIstudy of ACT clinical trial has shown complete regression on two of nine metastatic cervical cancer patients but no overall survival influence reported, indicating that further investigation is warranted promisingly . In addition, T‐cell immune checkpoint inhibitor such as pembrolizumab targeting the popular PD‐1‐PD‐L1 axis was found tolerant and promising in PD‐L1‐positive recurrent or metastatic cervical squamous cell cancer .…”

Section: New Concepts and Technologies For Early Prevention And Treatmentioning

confidence: 99%

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

2018

Cancer Medicine

220

140

View full text Add to dashboard Cite

Cervical cancer is the third most common cancer in women worldwide, with concepts and knowledge about its prevention and treatment evolving rapidly. Human papillomavirus (HPV) has been identified as a major factor that leads to cervical cancer, although HPV infection alone cannot cause the disease. In fact, HPV‐driven cancer is a small probability event because most infections are transient and could be cleared spontaneously by host immune system. With persistent HPV infection, decades are required for progression to cervical cancer. Therefore, this long time window provides golden opportunity for clinical intervention, and the fundament here is to elucidate the carcinogenic pattern and applicable targets during HPV‐host interaction. In this review, we discuss the key factors that contribute to the persistence of HPV and cervical carcinogenesis, emerging new concepts and technologies for cancer interventions, and more urgently, how these concepts and technologies might lead to clinical precision medicine which could provide prediction, prevention, and early treatment for patients.

show abstract

ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer

Cited by 15 publications

References 0 publications

Advances in immunotherapy for cervical cancer: recent developments and future directions

Advances in immunotherapy for cervical cancer: recent developments and future directions

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

Contact Info

Product

Resources

About